More from Stocks
Something's been nagging me about sentiment, so I went to Twitter to get to the bottom of it. Plus, what to expect from the Russell this week and a look at the S&P's head-and-shoulders top.
These recently downgraded names are displaying both quantitative and technical deterioration.
Here's how I'd play the SPDR S&P Biotech exchange-traded fund.
Trading in multiple time frames not only reduces risks, but also provides strategic flexibility. Let me show you what I mean and how to do it.
Here's why we believe 'higher for longer DUE to higher GDP' has a more dovish tone, and remain constructive for the rest of the year.